EIGRQ — Eiger Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $12.59m
- $28.27m
- $15.77m
Brief: Eiger Biopharmaceuticals Announces First Patient Enrolled In LIMT-2 A Phase 3 Study Of Peginterferon Lambda In Patients With Chronic Hepatitis Delta Virus Infection
Brief: Eiger Biopharmaceuticals Announces Second Positive Interim Analysis And Continuation Of Dosing Of Peginterferon Lambda In Phase 3 Together Study Of Newly Diagnosed Covid-19 Patients
Eiger BioPharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Eiger Biopharmaceuticals Announces Complete Enrollment Of Late-Stage Study Investigating Oral Agent, Lonafarnib, In Hepatitis Delta Virus
Brief: Eiger BioPharmaceuticals Inc Announces Interim Analysis And Continuation Of Dosing Of Peginterferon Lambda In Phase 3
Eiger BioPharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: Eiger Announces FDA Breakthrough Therapy Designation For Avexitide For Treatment Of Congenital Hyperinsulinism
Eiger BioPharmaceuticals Inc expected to post a loss of 55 cents a share - Earnings Preview
Eiger BioPharma up after dosing begins in COVID-19 outpatient study
Brief: Eiger Biopharmaceuticals Announces First Patients Dosed With Peginterferon Lambda In Phase 3 Together Study Of Newly Diagnosed Covid-19 Outpatients
Advisory: Stray alert on Eiger Biopharmaceuticals withdrawn
Eiger BioPharma up on positive data from pediatric disorder study
Brief: Eiger BioPharmaceuticals Inc Announces An Oral Poster Presentation Of Phase 2 Study Results Of Avexitide In Congenital Hyperinsulinism
Brief: Eiger Biopharmaceuticals Reports First Quarter 2021 Financial Results And Provides Business Update
Brief: Eiger Biopharmaceuticals Announces Peginterferon Lambda To Be Added To COVID-19 Study In Brazil
Brief: Eiger BioPharmaceuticals Appoints Commercial Expert And Industry Veteran Kim Sablich To Its Board Of Directors
U.S. RESEARCH ROUNDUP-Bluebird Bio, Mission Produce, Sally Beauty Holdings
Brief: Eiger BioPharmaceuticals Reports Fourth Quarter And Full Year 2020 Financial Results
Brief: Eiger Announces Publication Of Phase 2 Prevent Study Results Of Avexitide In Post-Bariatric Hypoglycemia In Journal Of Clinical Endocrinology & Metabolism